Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice.

doi:10.1016/j.dld.2014.12.004

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver - 1 Mar 2015

Cento Valeria, Tontodonati Monica, Di Maio Velia Chiara, Bellocchi Maria Concetta, Valenti Fabrizio, Manunta Alessandra, Fortuna Serena, Armenia Daniele, Carioti Luca, Antonucci Francesco Paolo, Bertoli Ada, Trave Francesca, Cacciatore Pierluigi, Angelico Mario, Navarra Pierluigi, Neumann Avidan U, Vecchiet Jacopo, Parruti Giustino, Babudieri Sergio, Perno Carlo Federico, Ceccherini-Silberstein Francesca

Abstract excerpt

BACKGROUND: The used first generation protease inhibitors may be hampered by virological failure in partially interferon-sensitive patients. AIM: To investigate early hepatitis C virus (HCV)-RNA decay and quasispecies modifications, and disclose viral dynamics underlying failure. METHODS: Viraemia decay at early time-points during telaprevir treatment was modelled according to Neumann et al. (1998). NS3-sequences...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Linear Models

Share to Oligopeptides

Share to Protease Inhibitors

Share to Ribavirin

Share to RNA Stability

Source

Open in PubMed

Identifiers

PMID: 25637450
DOI: 10.1016/j.dld.2014.12.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice.PMID 25637450Read ↗

HCV NS3 quasispecies in liver and plasma and dynamics of telaprevir-resistant variants in breakthrough patients assessed by UDPS: A case study.Semantic proximity Read ↗

Dynamic changes in HCV RNA levels and viral quasispecies in a patient with chronic hepatitis C after telaprevir-based treatment.Semantic proximity Read ↗

Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial.Semantic proximity Read ↗

Dynamic and rapid changes in viral quasispecies by UDPS in chronic hepatitis C patients receiving telaprevir-based therapy.Semantic proximity Read ↗

Efficacy and safety of telaprevir (TVR) triple therapy in a 'real-life' cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment.Semantic proximity Read ↗

Utility of detection of telaprevir-resistant variants for prediction of efficacy of treatment of hepatitis C virus genotype 1 infection.Semantic proximity Read ↗

Deep-Sequencing Analysis of the Gene Encoding the Hepatitis C Virus Nonstructural 3–4A Protease Confirms a Low Prevalence of Telaprevir-Resistant Variants at Baseline and the End of the REALIZE StudySemantic proximity Read ↗

Evaluation of Persistence of Resistant Variants with Ultra-Deep Pyrosequencing in Chronic Hepatitis C Patients Treated with TelaprevirSemantic proximity Read ↗

Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.Semantic proximity Read ↗

Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1.Semantic proximity Read ↗

Telaprevir for retreatment of HCV infection.Semantic proximity Read ↗

Incidence of virological failure and emergence of resistance with twice-daily vs every 8-h administration of telaprevir in the OPTIMIZE study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.